Good Morning, ASAM Chapter Presidents and Advocacy Leaders:
SAMHSA has recently posted the following message on its website:
Congress has taken action in the recent Consolidated Appropriations Act, 2023 that impacts federal requirements for Drug Enforcement Administration (DEA) registrants, including those involved in OUD treatment. SAMHSA and DEA are actively working to develop further guidance related to these changes. Please frequently check this webpage for further updates and guidance. Read here: https://www.samhsa.gov/medication-assisted-treatment
ASAM’s webpage has been updated, accordingly, to include a link to this new SAMHSA message here: https://www.asam.org/advocacy/practice-resources/buprenorphine-management
Thank you for your continued patience as we wait for further federal guidance.